
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PEPCID AC | Johnson & Johnson | N-020325 OTC | 1995-04-28 | 2 products, RLD |
| PEPCID AC | Johnson & Johnson | N-020801 OTC | 2007-12-17 | 1 products, RLD, RS |
| FAMOTIDINE | Sagent Pharmaceuticals | N-219935 RX | 2025-07-16 | 3 products, RLD, RS |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PEPCID COMPLETE | Johnson & Johnson | N-020958 OTC | 2000-10-16 | 1 products, RLD, RS |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DUEXIS | Horizon Therapeutics Public | N-022519 DISCN | 2011-04-23 | 1 products, RLD |
Brand Name | Status | Last Update |
|---|---|---|
| acid controller | ANDA | 2025-09-15 |
| acid reducer | ANDA | 2025-09-18 |
| acid reducer complete | ANDA | 2025-08-27 |
| acid reducer plus antacid | ANDA | 2025-08-11 |
| acid relief | ANDA | 2025-09-18 |
| amazon basic care acid reducer | ANDA | 2025-09-04 |
| basic care acid reducer | ANDA | 2025-02-10 |
| basic care dual action complete | ANDA | 2022-07-11 |
| basic care famotidine | ANDA | 2020-02-19 |
| basic care heartburn prevention | ANDA | 2025-09-18 |
Code | Description |
|---|---|
| S0028 | Injection, famotidine, 20 mg |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Adenocarcinoma | D000230 | — | — | — | 2 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 5 | — | — | — | — | 5 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 4 | — | — | — | — | 4 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 3 | — | — | — | — | 3 |
| Non-small-cell lung carcinoma | D002289 | — | — | 3 | — | — | — | — | 3 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | — | — | — | — | 2 |
| Lung neoplasms | D008175 | — | C34.90 | 2 | — | — | — | — | 2 |
| Colonic neoplasms | D003110 | — | C18 | 2 | — | — | — | — | 2 |
| Triple negative breast neoplasms | D064726 | — | — | 2 | — | — | — | — | 2 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | — | — | — | — | 2 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 1 | — | — | — | — | 1 |
| Drug common name | Famotidine |
| INN | famotidine |
| Description | Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour.
|
| Classification | Small molecule |
| Drug class | H2-receptor antagonists (cimetidine type) |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | NC(N)=Nc1nc(CSCC/C(N)=N/S(N)(=O)=O)cs1 |
| PDB | — |
| CAS-ID | 76824-35-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL902 |
| ChEBI ID | 4975 |
| PubChem CID | 5702160 |
| DrugBank | DB00927 |
| UNII ID | 5QZO15J2Z8 (ChemIDplus, GSRS) |













